Detalles de la búsqueda
1.
Perioperative Nivolumab in Resectable Lung Cancer.
N Engl J Med
; 390(19): 1756-1769, 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38749033
2.
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Lancet Oncol
; 25(2): 212-224, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38134948
3.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Lancet
; 384(9944): 665-73, 2014 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24933332
4.
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
Eur J Cancer
; 125: 49-57, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838405
5.
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 6(10): 1571-1580, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32880601
6.
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.
Lung Cancer
; 136: 74-79, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31446228
7.
Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.
Biochimie
; 154: 19-24, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30071258
8.
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Clin Lung Cancer
; 19(3): 270-279.e3, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29373274
9.
EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts.
Oncol Res Treat
; 41(10): 634-642, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30145586
10.
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Lung Cancer
; 93: 95-103, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26898621
11.
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
J Clin Oncol
; 30(17): 2055-62, 2012 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22547591
12.
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
J Clin Oncol
; 30(17): 2070-8, 2012 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22564989
13.
Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
J Thorac Oncol
; 6(4): 781-5, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21289522
14.
Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
J Thorac Oncol
; 9(4): e31-3, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24736087
15.
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
J Clin Oncol
; 27(28): 4787-92, 2009 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19720897
Resultados
1 -
15
de 15
1
Próxima >
>>